Pfizer Inc.’s Free Cash Flow Growth at a glance
Pfizer Inc. reports free cash flow growth of 105.2% for Dec 2024. The prior period recorded -81.6% (Dec 2023). Year over year the metric moved +186.8 pts (+228.9%). The rolling three-period average stands at 3.6%. Data last refreshed Dec 7, 2025, 2:49 AM.
Latest reading
105.2% · Dec 2024
YoY movement
+186.8 pts (+228.9%)
Rolling average
3.6%
Current Free Cash Flow Growth
105.2%
+186.8 pts
+228.9%
Rolling average
3.6%
Latest Value
105.2%
Dec 2024
YoY Change
+186.8 pts
Absolute
YoY Change %
+228.9%
Rate of change
3-Period Avg
3.6%
Smoothed
Narrative signal
Pfizer Inc.’s free cash flow growth stands at 105.2% for Dec 2024. Year-over-year, the metric shifted by +186.8 pts, translating into a +228.9% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How free cash flow growth shapes Pfizer Inc.'s story
As of Dec 2024, Pfizer Inc. reports free cash flow growth of 105.2%. Gauge reinvestment strength and capital return capacity using free cash flow growth over multiple reporting periods.
Cash flow versus earnings
Free cash flow growth can diverge from earnings due to working capital and capex swings. Track both to confirm quality.
Capital allocation insights
Rising free cash flow enables dividends, buybacks, and debt reduction—key levers for shareholder value.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.8%
Operating Margin
25.9%
Net Profit Margin
12.6%
Return on Equity
9.1%
Return on Assets
3.8%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Pfizer Inc. (PFE) FAQs
Answers tailored to Pfizer Inc.’s free cash flow growth profile using the latest Financial Modeling Prep data.
What is Pfizer Inc.'s current free cash flow growth?
As of Dec 2024, Pfizer Inc. reports free cash flow growth of 105.2%. This reading reflects the latest filings and price data for PFE.
How is Pfizer Inc.'s free cash flow growth trending year over year?
Year-over-year, the figure shifts by +186.8 pts (+228.9%). Pair this context with revenue growth and free cash flow signals to gauge momentum for PFE.
Why does free cash flow growth matter for Pfizer Inc.?
Free cash flow growth measures how quickly operating cash surplus expands compared with the prior period. For Pfizer Inc., operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Pfizer Inc.'s free cash flow growth above its recent average?
Pfizer Inc.'s rolling three-period average sits at 3.6%. Comparing the latest reading of 105.2% to that baseline highlights whether momentum is building or fading for PFE.
How frequently is Pfizer Inc.'s free cash flow growth refreshed?
Data for PFE was last refreshed on Dec 7, 2025, 2:49 AM and updates automatically every 24 hours, keeping your valuation inputs current.